Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating[...]
Pharmacokinetics and Serum Virus Neutralizing Antibody Titers Following[...]
Results from a Phase 1 First in human Study of Pemivibart: an[...]
09/19/2024 | Press release | Distributed by Public on 09/19/2024 14:05
Please select the service you want to use:
Smartlinks | Alliance Entertainment Holding Corporation | News | Company News | Consumer Electronics Retailers | OTC Markets | NYSE American | NYSE ARCA Equities | Nasdaq Capital Market | Cboe BZX Exchange | Cboe BYX Exchange | Cboe EDGA Exchange | Cboe EDGX Exchange | FINRA Alternative Display Facility (ADF) | Nasdaq BX | Nasdaq PSX | NYSE Chicago
Back
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact